Locust Walk Insights
LOCUST WALK INSIGHTS
2022 Q2 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2022 Second Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.
2022 Q1 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2022 First Quarter Report applies the latest data to analyze current activities in the life sciences deal...
Breakthrough Innovation Reports: Oncology IPS-Effector Cell Therapies
The CAR-T and oncology cell therapy landscape has broadly seen significant continued development, with over 2,000 therapies in development and ~1,350 active trials globally
Breakthrough Innovation Reports: Regenerative Medicine iPS-Cell Therapy Investment Insights and Emerging Players
Induced pluripotent stem cell (iPSC) technology has the potential to transform the treatment landscape and bring curative options to patients. iPSC-derived cells have the potential to address a wide range of diseases and serve as a fertile ground for new investment...
2021 Year End Report
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Year End Report applies the latest data to analyze current activities in the life sciences deal landscape.
Bought Not Sold
How do you start an M&A discussion? Locust Walk has conducted an extensive study of mergers and acquisitions in biopharma completed in the past three years and uncovered an interesting trend leaders need to understand: the majority of acquirers only became...
2021 Q3 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Q3 Report: Global Trends in Biopharma Transactions applies the latest data to analyze...
iPSC Market Overview
In this report you can find an overview and analysis of the following across the iPSC market: Summary of iPS-derived cell therapy development landscape and key clinical trials IPO and private financing activity and performance Public market performance relative to...
2021 Q2 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Q2 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal...
Crossover Evolution: The Evolving Role of the Crossover Financing Round
The Covid-19 pandemic was the biggest biopharma news of 2020. It may be hard to remember now, but in March of last year, biotech indices had quickly nose-dived, along with the broader market, as the reality of the pandemic became...
2021 Q1 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Q1 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal...
Boston Business Journal: Life sciences firm Locust Walk’s plans for its $175M SPAC
Geoff Meyerson co-founded Locust Walk, a Boston-based life sciences consulting firm, on Sept. 15, 2008, the same day that Lehman Brothers filed for bankruptcy and Merrill Lynch sold itself to Bank of America. Meyerson said he “figured the world didn’t need another...
Locust Walk 2020 Year End Report
Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings. Our 2020 Year End Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal...
Doubling Down: The Power of Asset Diversification in a Time of Robust Access to Capital
Q3 Report: Global Trends in Biopharma Transactions
Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings. Our Q3 2020 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal landscape. ...